Denali Therapeutics Inc. cotiza a 18.40 USD y tiene una capitalización bursátil de $2.9B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.68 | $-0.69 | $-0.73 |
| Estimado | $-0.37 | $-0.47 | $-0.71 | $-0.75 |
| Sorpresa | — | -44.7% | +2.8% | +2.7% |
| Métrica | DNLI | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -50.6% | -40.4% | -10.2% |
| ROA | -44.8% | -32.0% | -12.8% |
| Current Ratio | 9.16 | 2.84 | +6.32 |
| Debt / Equity | — | 0.28 | — |